This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment
followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03
administered once weekly to ambulant boys with DMD, who have a DMD mutation amenable to exon
50 skipping.